Corneal Crosslinking for Treatment of Corneal Neovascularization

See also
Status	Clinical Trial	Phase
Completed	`NCT00555594` - Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization	Phase 2/Phase 3
Completed	`NCT00004430` - Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization	N/A
Completed	`NCT00769145` - Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery	Phase 1
Completed	`NCT01257750` - Treatment of Corneal Neovascularization With Topical Pazopanib	Phase 1/Phase 2
Active, not recruiting	`NCT00992849` - Bevacizumab for the Treatment of Corneal Neovascularization	Phase 2
Withdrawn	`NCT00515684` - Corneal Thinning During Topical Bevacizumab Therapy	N/A
Terminated	`NCT02797704` - Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization	Phase 1/Phase 2
Terminated	`NCT01868360` - Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea	Phase 1
Withdrawn	`NCT02042027` - Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions	Phase 1
Recruiting	`NCT04215393` - An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization	Phase 1
Completed	`NCT00797303` - The Effect of Bevacizumab on Corneal Neovascularization	Phase 4
Recruiting	`NCT05659940` - Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
Completed	`NCT00559936` - Topical Avastin for Treatment of Corneal Neovascularization	Phase 1
Completed	`NCT01072357` - Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival	Phase 1/Phase 2
Recruiting	`NCT04620109` - Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment	Phase 1
Completed	`NCT00512876` - Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization	N/A
Recruiting	`NCT05011916` - The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization	Phase 1/Phase 2
Completed	`NCT01996826` - A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival	Phase 1/Phase 2
Terminated	`NCT00915590` - Topical IL-1-Ra for Treatment of Corneal Neovascularization	Phase 1/Phase 2
Completed	`NCT00681889` - Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)	Phase 1

NCT number	NCT04787471
Study type	Interventional
Source	Price Vision Group
Contact	Marianne Price, PhD
Phone	317-814-2990
Email	mprice@cornea.org
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	May 3, 2021
Completion date	July 15, 2025

Corneal Crosslinking for Treatment of Corneal Neovascularization

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms